AxoGen (AXGN) to Release Earnings on Thursday

AxoGen (NASDAQ:AXGN - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect AxoGen to post earnings of ($0.01) per share and revenue of $48.35 million for the quarter.

AxoGen Trading Down 1.0 %

Shares of AxoGen stock traded down $0.17 during midday trading on Tuesday, reaching $16.02. 17,819 shares of the company's stock traded hands, compared to its average volume of 426,811. The stock has a 50 day moving average of $17.38 and a 200-day moving average of $16.21. AxoGen has a 12 month low of $5.55 and a 12 month high of $21.00. The company has a market cap of $710.17 million, a PE ratio of -49.95 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Insider Activity at AxoGen

In related news, insider Erick Wayne Devinney sold 15,111 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now owns 217,762 shares of the company's stock, valued at approximately $3,810,835. This represents a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. This trade represents a 4.86 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Lake Street Capital initiated coverage on shares of AxoGen in a report on Monday, March 17th. They set a "buy" rating and a $30.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $24.00 price target on shares of AxoGen in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group upped their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $22.60.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.